Here are three things to know. 1. The upfront payments were not disclosed, however, Kineta is eligible to receive up to $359 million on top of royalty payments. 2. Genentech has the ability to license technologies developed from the collaborations. 3. Early tests of the drug are displaying disease-modifying effects, such as reduced information and nerve protection. 4. Roche purchased Genentech for $46.8 billion in 2009. 5. Kineta was founded in 2008 to develop drugs for chronic pain, autoimmune and infectious diseases. More articles on devices and implants: NovoStitch Pro Meniscal Repair System receives FDA 510(k) clearance: 4 insights Global spinal fusion devices market to grow at 4.6% CAGR through 2025: 4 observations Dr. Richard Moore performs 1st surgery with Zimmer Biomet's Persona Trabecular Metal Tibia: 5 notes